Moolec Science's EBIT per Share for the
six
months ended in Dec. 2025 was $-12.28.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-251.00.
During the past 12 months, the average EBIT per Share Growth Rate of Moolec Science was -113.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 17.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Moolec Science's EBIT per Share or its related term are showing as below:
MLEC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 17.7 Med: 17.7 Max: 17.7
Current: 17.7
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Moolec Science was 17.70% per year. The lowest was 17.70% per year. And the median was 17.70% per year.
MLEC's 3-Year EBIT Growth Rate is ranked better than 52.41% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs MLEC: 17.70
Moolec Science's EBIT for the
six
months ended in Dec. 2025 was $-8.9 Mil.
Moolec Science (NAS:MLEC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Moolec Science EBIT per Share Related Terms
Moolec Science EBIT per Share Historical Data
* Premium members only.
The historical data trend for Moolec Science's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-251.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science (MLEC) has a EBIT per Share of $-251.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #562 out of 1181 companies in the Biotechnology industry, placing it in the top 47.6%.
Is Moolec Science's EBIT per Share too high?
Moolec Science's current EBIT per Share is $-251.00. Based on the distribution chart, Moolec Science ranks #562 out of 1181 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Moolec Science has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's EBIT per Share compare to GNPX and ADIL?
According to the Biotechnology industry distribution chart, Moolec Science ranks #562 out of 1181 companies for EBIT per Share. This puts Moolec Science in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Moolec Science and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moolec Science's current EBIT per Share is $-251.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $8.09 — trading 90.5% below its estimated fair value. The current EBIT per Share is $-251.00. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Moolec Science (MLEC), the current EBIT per Share is $-251.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $8.09 is trading 90.5% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
EBIT per Share: $-251.00
GF Value™: $84.84 vs. price of $8.09 (90.5% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for MLEC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
